Quantitative estimation of rare adverse events which follow a biological progression:: a new model applied to chronic NSAID use

被引:258
作者
Tramèr, MR
Moore, RA
Reynolds, DJM
McQuay, HJ
机构
[1] Hop Univ, Dept APSIC, Div Anesthesiol, CH-1211 Geneva 14, Switzerland
[2] Oxford Radcliffe Hosp, Nuffield Dept Anaesthet, Oxford OX3 7LJ, England
[3] Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England
关键词
meta-analysis; adverse event; adverse drug reaction; non-steroidal anti-inflammatory drug; aspirin; systematic review; complications;
D O I
10.1016/S0304-3959(99)00267-5
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Randomised controlled trials (RCTs) alone are unlikely to provide reliable estimates of the incidence of rare events because of their limited size. Cohort, case control, and other observational studies have large numbers but are vulnerable to various kinds of bias. Wanting to estimate the risk of death from bleeding or perforated gastroduodenal ulcers with chronic usage of non-steroidal anti-inflammatory drugs (NSAIDs) with greater precision, we developed a model to quantify the frequency of rare adverse events which follow a biological progression. The model combined data from both RCTs and observational studies. We searched systematically for any report of chronic (greater than or equal to 2 months) use of NSAIDs which gave information on gastroduodenal ulcer, bleed or perforation, death due to these complications, or progression from one level of harm to the next. Fifteen RCTs (19 364 patients exposed to NSAIDs for 2-60 months), three cohort studies (215 076 patients redeeming a NSAID prescription over a 3-12 month period), six case-control studies (2957 cases) and 20 case series (7406), and case reports (4447) were analysed. In RCTs the incidence of bleeding or perforation in 6822 patients exposed to NSAIDs was 0.69%; two deaths occurred. Of 11 040 patients with bleeding or perforation with or without NSAID exposure across all reports, 6-16% (average 12%) died; the risk was lowest in RCTs and highest in case reports. Death from bleeding or perforation in all controls not exposed to NSAIDs occurred in 18 out of 849 489 (0.002%). From these numbers we calculated the number-needed-to-treat for one patient to die due to gastroduodenal complications with chronic (greater than or equal to 2 months) NSAIDs as 1/((0.69 x {6-16%, average 12%}) - 0.002%)) = 909-2500 (average 1220). On average 1 in 1200 patients taking NSAIDs for at least 2 months will die from gastroduodenal complications who would not have died had they not taken NSAIDs. This extrapolates to about 2000 deaths each year in the UK. (C) 2000 International Association for the Study of Pain. Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:169 / 182
页数:14
相关论文
共 74 条
[1]  
Abbasakoor F, 1995, IRISH MED J, V88, P207
[2]   MISOPROSTOL COADMINISTERED WITH DICLOFENAC FOR PREVENTION OF GASTRODUODENAL ULCERS - A ONE-YEAR STUDY [J].
AGRAWAL, NM ;
VANKERCKHOVE, HEJM ;
ERHARDT, LJ ;
GEIS, GS .
DIGESTIVE DISEASES AND SCIENCES, 1995, 40 (05) :1125-1131
[3]   PERFORATED PEPTIC-ULCER IN THE HUNTER REGION - A REVIEW OF 174 CASES [J].
AGREZ, MV ;
SENTHISELVAN, S ;
HENRY, DA ;
MITCHELL, A ;
DUGGAN, JM .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1992, 62 (05) :338-343
[4]  
Andrew Moore R, 1999, J MED ECON, V2, P45
[5]   NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND LIFE THREATENING COMPLICATIONS OF PEPTIC-ULCERATION [J].
ARMSTRONG, CP ;
BLOWER, AL .
GUT, 1987, 28 (05) :527-532
[6]   NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND GASTROINTESTINAL-BLEEDING - A CASE-CONTROL STUDY [J].
BARTLE, WR ;
GUPTA, AK ;
LAZOR, J .
ARCHIVES OF INTERNAL MEDICINE, 1986, 146 (12) :2365-2367
[7]   NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND HOSPITALIZATION FOR GASTROESOPHAGEAL BLEEDING IN THE ELDERLY [J].
BEARD, K ;
WALKER, AM ;
PERERA, DR ;
JICK, H .
ARCHIVES OF INTERNAL MEDICINE, 1987, 147 (09) :1621-1623
[8]  
Black N, 1996, BRIT MED J, V312, P1215
[10]   Emergency admissions for upper gastrointestinal disease and their relation to NSAID use [J].
Blower, AL ;
Brooks, A ;
Fenn, GC ;
Hill, A ;
Pearce, MY ;
Morant, S ;
Bardhan, KD .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (02) :283-291